GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » EV-to-EBIT

BOLD (Boundless Bio) EV-to-EBIT : 1.75 (As of Oct. 31, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Boundless Bio's Enterprise Value is $-113.47 Mil. Boundless Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-65.02 Mil. Therefore, Boundless Bio's EV-to-EBIT for today is 1.75.

The historical rank and industry rank for Boundless Bio's EV-to-EBIT or its related term are showing as below:

BOLD' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.45   Med: 0   Max: 1.87
Current: 1.75

During the past 3 years, the highest EV-to-EBIT of Boundless Bio was 1.87. The lowest was -7.45. And the median was 0.00.

BOLD's EV-to-EBIT is ranked better than
61.81% of 419 companies
in the Biotechnology industry
Industry Median: 10.01 vs BOLD: 1.75

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Boundless Bio's Enterprise Value for the quarter that ended in Jun. 2024 was $-92.33 Mil. Boundless Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-65.02 Mil. Boundless Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 70.42%.

Boundless Bio EV-to-EBIT Historical Data

The historical data trend for Boundless Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio EV-to-EBIT Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
- - -

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -3.58 1.42

Competitive Comparison of Boundless Bio's EV-to-EBIT

For the Biotechnology subindustry, Boundless Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boundless Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Boundless Bio's EV-to-EBIT falls into.


Boundless Bio EV-to-EBIT Calculation

Boundless Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-113.470/-65.023
=1.75

Boundless Bio's current Enterprise Value is $-113.47 Mil.
Boundless Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boundless Bio  (NAS:BOLD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Boundless Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-65.023/-92.329633
=70.42 %

Boundless Bio's Enterprise Value for the quarter that ended in Jun. 2024 was $-92.33 Mil.
Boundless Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boundless Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Boundless Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » EV-to-EBIT
Comparable Companies
Traded in Other Exchanges
N/A
Address
9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121
Website
https://www.boundlessbio.com
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.